For years, compounding pharmacies operated in a specialized corner of the pharmaceutical industry by serving patients whose medical needs could not be met by commercially available medications. Today, compounding has moved much closer to the center of the healthcare conversation.
The rapid rise in demand for GLP-1 medications has helped accelerate that shift. As demand for medications such as semaglutide and tirzepatide surged, compounded medications became an increasingly visible part of the market. At the same time, federal and state regulators have increased their attention on how compounded drugs are prepared, distributed and supplied to patients.
For compounding pharmacies, that creates a complicated reality. Growth can mean new opportunities, but expanding into additional states can also mean navigating an increasingly complex web of pharmacy licenses, nonresident pharmacy requirements, sterile compounding permits, outsourcing facility requirements, inspections and state-specific regulations.
The result is a market where simply obtaining a pharmacy license may no longer be enough. Compounding pharmacies need a licensing and compliance strategy that reflects what they actually do, where they operate and how their products move across state lines.
GLP-1s Put Compounding in the Spotlight
The explosive demand for GLP-1 medications has fundamentally changed the visibility of pharmaceutical compounding.
Medications containing active ingredients such as semaglutide and tirzepatide have become widely associated with weight management and metabolic health. The popularity of these medications has created enormous demand, while availability, cost and other market factors have contributed to interest in compounded alternatives.
That demand has brought increased attention to the compounding pharmacy industry from patients, healthcare providers, lawmakers and regulators.
The regulatory environment surrounding GLP-1 compounding has also continued to evolve. The FDA’s current compounding policy materials include specific actions concerning bulk drug substances used in 503B outsourcing facilities, including a 2026 proposal involving semaglutide, tirzepatide and liraglutide.
This illustrates an important point for compounding pharmacies: regulatory compliance is not static.
A pharmacy can be compliant with the rules that applied when it obtained a license and still face a different regulatory landscape months or years later.
What Makes a Compounding Pharmacy Different?
Compounding pharmacies are not simply traditional pharmacies producing a different type of prescription.
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, traditional pharmacy compounding is generally performed by a licensed pharmacist in a state-licensed pharmacy, subject to the conditions established under federal law. Section 503B applies to outsourcing facilities, which compound drugs under a different federal framework and are subject to federal current good manufacturing practice requirements.
That distinction matters.
A 503A compounding pharmacy typically operates as a pharmacy serving individual patient prescriptions and is heavily intertwined with state pharmacy laws and regulations. A 503B outsourcing facility, by contrast, operates under a framework specifically established for outsourcing facilities and can manufacture compounded drugs on a larger scale.
The difference between 503A and 503B is therefore more than terminology. It can affect the facility’s licensing obligations, inspection requirements, operational model and regulatory exposure.
And once a compounding pharmacy begins serving patients or business partners across state lines, the complexity can increase considerably.
The State Licensing Problem: One Pharmacy, Many Regulatory Environments
One of the biggest misconceptions surrounding multistate pharmacy operations is that a pharmacy licensed in its home state can simply begin shipping prescriptions throughout the country.
That is not how the regulatory landscape works.
States establish their own requirements for pharmacies located outside their borders. Depending on the state and the pharmacy’s activities, an out-of-state compounding pharmacy may need a nonresident pharmacy license, a sterile compounding permit, an outsourcing facility license or another state-specific authorization.
New York, for example, requires certain nonresident establishments that ship, mail or deliver prescription drugs or devices into the state to be registered. Its requirements specifically encompass nonresident pharmacies and certain manufacturers, wholesalers and outsourcing facilities.
Florida provides another example of how compounding can create an additional licensing layer. A nonresident pharmacy or outsourcing facility shipping compounded sterile products into the state must hold a nonresident sterile compounding permit.
California similarly distinguishes between nonresident pharmacies, sterile compounding operations and 503B outsourcing facilities, with separate licensing considerations for entities conducting those activities. California’s requirements also include specific obligations for nonresident pharmacy Pharmacists-in-Charge beginning July 1, 2026.
These examples demonstrate why a national licensing strategy cannot rely on a single checklist.
The question is not simply, “Do we have a pharmacy license?”
The more important question is, “What are we doing, where are we doing it, and what does each state require us to do it legally?”
Sterile Compounding Creates Another Layer of Complexity
Sterile compounding can create additional licensing and inspection requirements that do not necessarily apply to conventional pharmacy operations. States may require a separate sterile compounding permit, inspections, specific facility standards or documentation demonstrating compliance with applicable compounding requirements.
For example, California requires pharmacies compounding sterile drugs for injection, ophthalmic administration or inhalation to obtain a sterile compounding pharmacy license. The state requires inspection before issuing or renewing that license.
Other states have developed their own approaches to regulating sterile compounding and outsourcing facilities.
Michigan’s current regulatory materials, for example, identify inspection requirements associated with renewal of a pharmacy license for certain nonresident facilities that compound under Section 503B.
For a pharmacy expanding nationally, these differences can become operationally significant.
A license application may require an inspection report from the home state. Another jurisdiction may conduct its own inspection. One state may require a separate permit for sterile compounding, while another may incorporate requirements into a broader pharmacy or outsourcing facility license.
The result is a regulatory patchwork that requires ongoing attention.
503A vs. 503B: Why the Distinction Matters
The growth of compounding has also increased the importance of understanding the difference between 503A and 503B operations.
A 503A pharmacy operates within the traditional pharmacy compounding framework, while a 503B outsourcing facility is subject to a distinct federal regulatory structure. The FDA notes that 503A and 503B compounders have different statutory frameworks and exemptions.
That distinction can influence how a facility approaches federal registration, state licensing and distribution.
For companies operating 503B outsourcing facilities, the licensing analysis can become particularly complicated because a facility may need to account for both its FDA registration and the individual requirements imposed by states into which it distributes compounded products.
Some states may treat an outsourcing facility differently from a traditional pharmacy. Others may impose requirements that depend on whether the facility is shipping sterile products, whether it is located inside or outside the state, and what type of activity it conducts.
This is why assuming that “503B registered with FDA” automatically means “authorized to operate everywhere” can create significant compliance risk.
The Regulatory Landscape Is Moving
The biggest challenge for compounding pharmacies may not be obtaining their initial licenses. It may be keeping those licenses and operations compliant as requirements change.
State pharmacy boards regularly update statutes, regulations, applications, renewal requirements and operational standards. New legislation can create additional obligations, while changes to existing rules can alter what a pharmacy needs to maintain its authority to operate.
The environment surrounding compounded GLP-1 medications demonstrates how quickly the regulatory conversation can change. At the federal level, the FDA continues to update its compounding policies and guidance, including policies addressing bulk drug substances used by 503A and 503B compounders. At the state level, regulators are also taking a closer look at compounding operations.
For a pharmacy operating in one state, keeping up with these changes can be challenging. For a pharmacy licensed in 20, 30 or 50 states, it becomes a fundamentally different problem.
Expansion Can Create Licensing Exposure
Consider a compounding pharmacy that begins in one state and develops a successful mail-order business.
The business grows. Patient demand increases. Telehealth partnerships create new opportunities. The pharmacy begins serving patients in additional states.
From a commercial perspective, this may look like straightforward growth.
From a licensing perspective, however, every new state can introduce a new regulatory analysis.
- Does the state require a nonresident pharmacy license?
- Does it require a separate sterile compounding permit?
- Does it have special requirements for compounded medications?
- Does the state require an inspection?
- Does it require a resident agent?
- Are there specific Pharmacist-in-Charge requirements?
- Does the state’s definition of pharmacy, manufacturer, wholesaler or outsourcing facility affect the company’s licensing obligations?
And perhaps most importantly, have any of those requirements changed since the pharmacy last reviewed its portfolio?
These are not questions that can be answered once and then forgotten.
The Future of Compounding Will Require Proactive Compliance
The growth of compounding pharmacies is unlikely to eliminate the need for specialized medications. In many cases, compounding can provide important solutions for patients when commercially available products do not meet a particular clinical need.
But the industry’s growth also means greater regulatory visibility.
The pharmacies that are best positioned for continued growth will be those that treat licensing and regulatory compliance as an ongoing business function rather than an administrative task.
That means understanding the distinction between 503A and 503B operations, identifying every state where a license or permit may be required, maintaining licenses before they expire and monitoring regulatory changes that could affect the business model.
It also means recognizing that a company’s licensing footprint should evolve as its operations evolve.
A pharmacy’s original licensing strategy may have been appropriate when it served patients in a handful of states. It may not remain appropriate after expanding nationwide, adding sterile compounding, entering into new distribution relationships or changing how it markets and dispenses compounded medications.
Keeping Compounding Pharmacies Ahead of Regulatory Change
At State License Servicing, we help compounding pharmacies navigate the state licensing requirements that come with operating and expanding a modern pharmacy business.
Our team helps pharmacies obtain and renew state pharmacy licenses and related authorizations, including the licensing considerations that can arise for mail-order, 503A and 503B compounding operations.
But licensing is only part of the challenge.
We also help companies monitor regulatory changes across all 50 states, the District of Columbia and U.S. territories so they can identify changes that may affect their operations, licenses or compliance obligations.
For a rapidly evolving industry like pharmaceutical compounding, knowing what the rules are today is important. Knowing when those rules change can be even more important.
As compounding pharmacies continue to grow, particularly in response to demand for GLP-1 medications and other specialized therapies, proactive state licensing and regulatory monitoring will become increasingly critical.
The future of compounding will not simply belong to the pharmacies that can meet demand. It will belong to the pharmacies that can scale while keeping pace with the regulatory environment around them.